5/2/2019 7:04:58 AM
Teva Q1 Non-GAAP EPS $0.60; GAAP Loss Per Share $0.10
4/23/2019 9:09:48 AM
Compass Minerals Names Kevin Crutchfield President And CEO
4/23/2019 9:07:54 AM
Teva Discontinues Clinical Development Program For Use Of Fremanezumab In Cluster Headaches
4/10/2019 8:11:36 AM
Teva Enters New $2.3 Bln Unsecured Revolving Credit Facility
4/1/2019 8:30:39 AM
Teva: AJOVY Gets EU Approval Offering Patients First, Only Anti-CGRP Treatment
3/18/2019 7:05:34 AM
Novo Nordisk Settles US Patent Litigation Case On Victoza With Teva
2/13/2019 7:04:29 AM
Teva Q4 Non-GAAP EPS $0.53, GAAP Loss Per Share $2.85
2/6/2019 11:26:15 AM
Teva Announces U.S. Launch Of A Generic Version Of Sabril
2/5/2019 7:37:01 PM
Teva Announces Launch Of ALYQ, Generic Version Of ADCIRCA In U.S.
2/1/2019 6:54:32 AM
Teva Receives Positive CHMP Opinion For AJOVY For Prophylaxis Of Migraine In Adults